TY - JOUR
AU - Farkas, Katalin
AU - Varga, Marina
AU - Dinnyes, Izabella
AU - Rem, Lili
AU - Telkes, Gábor
AU - Wágner, László József
AU - Remport, Ádám
AU - Piros, László
AU - Szijártó, Attila
AU - Huszty, Gergely
TI - Low-Dose vs Standard-Dose Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplantation: A Single-Center Retrospective Analysis
JF - TRANSPLANTATION PROCEEDINGS
J2 - TRANSPLANT PROC
VL - 56
PY - 2024
IS - 1
SP - 105
EP - 110
PG - 6
SN - 0041-1345
DO - 10.1016/j.transproceed.2023.11.021
UR - https://m2.mtmt.hu/api/publication/34501723
ID - 34501723
AB - Prophylactic administration of valganciclovir (VG) is an accepted method for the prevention of cytomegalovirus (CMV) infection after kidney transplantation (KTx). The standard dosage of oral VG is 900 mg/day, adjusted to renal function. There is growing evidence that low-dose 450 mg/day VG might be safe and effective. We compared low-dose vs standard-dose prophylaxis after KTx in a single-center follow-up study.Data from 603 renal transplantations at a single center were retrospectively analyzed (2011-2014, 12-month follow-up). Recipients with donor IgG positive-recipient IgG positive (D+/R+), (D+/R-), and (D-/R+) CMV serostatus were routinely treated with 450 mg/day VG for 3 months. Based on the same prophylactic dose, patients could be categorized into two groups according to their postoperative renal function: those receiving standard-dose VG due to a lower estimated glomerular filtration rate (eGFR) (average eGFR<60 mL/min/1.73 m2) and those receiving low-dose VG due to higher eGFR (average eGFR>60 mL/min/1.73 m2).Estimated glomerular filtration rate-based VG serum alterations significantly affected the risk of CMV infection with a higher incidence in higher VG levels (standard-dose: 357 patients, CMV: 33 cases (9.2 %); low-dose: 246 patients, CMV: 10 cases (4.1%). The occurrence of known risk factors: serologic risk distribution and rate of induction therapy were not statistically different between the 2 groups. Treatment of an acute rejection episode influenced the infection rate significantly in the standard-dose group. As a side effect of prophylaxis, leucopenia (<3G/L) was 2.46 times higher in standard-dose vs low-dose group.Low-dose VG administration is safe and non-inferior to the standard dose in the prophylaxis of CMV infection after KTx.
LA - English
DB - MTMT
ER -
TY - CHAP
AU - Huszty, Gergely
AU - Kóbori, László
AU - Piros, László
ED - Sándor, József
TI - Transzplantációs alapismeretek
T2 - Sebészet tankönyv és tudománytörténet: traumatológiai, szülészeti és urológiai alapismeretekkel kiegészítve
PB - Semmelweis Kiadó és Multimédia Stúdió
CY - Budapest
SN - 9789633315910
PY - 2023
SP - 527
EP - 532
PG - 6
UR - https://m2.mtmt.hu/api/publication/34538815
ID - 34538815
LA - Hungarian
DB - MTMT
ER -
TY - JOUR
AU - Huszty, Gergely
AU - Igaz, Péter
TI - Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered?
JF - ENDOCRINE-RELATED CANCER
J2 - ENDOCR-RELAT CANCER
VL - 31
PY - 2023
IS - 1
SN - 1351-0088
DO - 10.1530/ERC-23-0220
UR - https://m2.mtmt.hu/api/publication/34422426
ID - 34422426
LA - English
DB - MTMT
ER -
TY - JOUR
AU - Huszty, Gergely
AU - Bihari, László
AU - Gráf, László
AU - Szijártó, Attila
AU - Máté, Szabolcs
TI - A peritoneális felszín tumorainak sebészete – citoreduktív sebészet és hipertermiás intraperitoneális kemoterápia
JF - MAGYAR ONKOLÓGIA
J2 - MAGYAR ONKOLÓGIA
VL - 67
PY - 2023
IS - 3
SP - 247
EP - 258
PG - 12
SN - 0025-0244
UR - https://m2.mtmt.hu/api/publication/34167039
ID - 34167039
AB - Peritoneal carcinosis has historically been considered as inoperable, although the technique of its resesection together with high dose intraperitoneal chemotherapy potentiated by heat has been described decades ago. It has not became a widely practiced routine except in specialized centers - the complex technique, weakly standardized but resource demanding chemotherapy, lacking financial background and the many times questionable clinical benefit at a cost of high surgical load might have been the key factors. Refined technology, developing chemotherapy protocols together with growing clinical evidence are now more sharply delineating the range of indications where the procedure might be beneficial, increases survival, or is the only curative therapy. These include tumors of the appendix and pseudomyxoma peritonei, mesothelioma, and selected cases of ovarian, colorectal and gastric cancer. In addition to technical description of the intervention, we summarize the currently valid indications and describe our institutional protocol for the treatment of appendiceal malignancies.
LA - Hungarian
DB - MTMT
ER -
TY - JOUR
AU - Stark, Júlia
AU - Tőke, Judit
AU - Huszty, Gergely
AU - Nagy, Péter
AU - Bedics, Gábor
AU - Bödör, Csaba
AU - Tímár, József
AU - Tóth, Miklós
TI - Parathyroid cancer with MTOR gene mutation. Case report and review of the literature
TS - Case report and review of the literature
JF - ANNALES D ENDOCRINOLOGIE
J2 - ANN ENDOCRINOL-PARIS
VL - 84
PY - 2023
IS - 6
SP - 761
EP - 763
PG - 3
SN - 0003-4266
DO - 10.1016/j.ando.2023.06.003
UR - https://m2.mtmt.hu/api/publication/34081713
ID - 34081713
LA - English
DB - MTMT
ER -
TY - JOUR
AU - Nagy, Gergely
AU - Gerlei, Zsuzsanna
AU - Haboub-Sandil, Anita
AU - Görög, Dénes
AU - Szabó, József
AU - Kóbori, László
AU - Huszty, Gergely
AU - Bihari, László
AU - Rózsa, Balázs
AU - Pőcze, Balázs
AU - Máthé, Zoltán
AU - Piros, László
TI - Optimizing Survival for Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Report and Current Perspectives
JF - TRANSPLANTATION PROCEEDINGS
J2 - TRANSPLANT PROC
VL - 54
PY - 2022
IS - 9
SP - 2593
EP - 2597
PG - 5
SN - 0041-1345
DO - 10.1016/j.transproceed.2022.10.048
UR - https://m2.mtmt.hu/api/publication/33271361
ID - 33271361
AB - Hepatocellular carcinoma (HCC) is the leading primary liver tumor and a main indication for transplant. Transplant criteria are based on clinicopathologic features, meanwhile adequate downstaging and molecular mechanisms are getting more attention in evolving therapeutic algorithm of HCC. The aim of our study was to overview the results of the Hungarian Liver Transplant Program in the field of HCC and introduce new aspects of personalized treatment options.We performed retrospective analysis of survival and tumor recurrence of HCC-associated liver transplant recipients between October 2013 and December 2020. Patients were categorized in Milan criteria (MC), beyond MC but within University of California, San Francisco (UCSF), and beyond UCSF criteria groups after pathologic examination of the explanted liver. Demographic data and preoperative locoregional treatments were assessed.A total of 529 primer liver transplants were performed, 88 because of HCC. A total of 87 patients had underlying cirrhosis because of hepatitis C (54%), alcohol-related liver disease (33.7%), hepatitis B (4.5%), or unknown etiology. A total of 55.6% of the patients had at least one locoregional treatment. A total of 67.4% of the patients were within MC, 5.6% were within UCSF criteria, and 27% were beyond UCSF criteria. The 1-, 3-, and 5-year survival rates were 80%, 79%, and 75%. The outcome was better in early-stage tumors, but the difference was not significant (P = .745) CONCLUSIONS: The favorable survival in our department legitimates the strict transplant criteria of HCC. Adequate locoregional therapy as downstaging can expand recipient pool. Molecular tumor profiling may lead to personalized treatment of HCC.
LA - English
DB - MTMT
ER -
TY - JOUR
AU - Meltzer, Anna Zsófia
AU - Fintha, Attila
AU - Cseprekál, Orsolya
AU - Somogyi, Dóra
AU - Szabó, József
AU - Kóbori, László
AU - Rózsa, Balázs
AU - Piros, László
AU - Huszty, Gergely
TI - Graft Arterial Dissection and Thrombosis After Kidney Transplantation With Undiagnosed Fibromuscular Dysplasia From a Deceased Donor: Case Report and Review
JF - TRANSPLANTATION PROCEEDINGS
J2 - TRANSPLANT PROC
VL - 54
PY - 2022
IS - 9
SP - 2603
EP - 2607
PG - 5
SN - 0041-1345
DO - 10.1016/j.transproceed.2022.10.049
UR - https://m2.mtmt.hu/api/publication/33257643
ID - 33257643
AB - Fibromuscular dysplasia (FMD), a relatively frequent arterial deformity with an estimated prevalence of 2% to 6% has been sporadically reported during deceased donor kidney donations. Only 8 case reports are available in the previous literature.In our work, implantation of 2 kidneys from the same deceased donor with macroscopically evident and later histologically confirmed FMD are presented, one of which ended up as acute arterial complication. Renal arteries were cut short to allow safe implantation, but arterial dissection and thrombosis led to graft loss in the early perioperative period in the latter case.Although resection of the arterial segments affected by FMD as a routine may allow implantation, macroscopically healthy-looking arteries might still be affected and thus carry elevated postoperative risk. The aim of our case report is to make proposal for an onsite diagnosis of FMD in case of clinical suspicion.
LA - English
DB - MTMT
ER -
TY - JOUR
AU - Tőke, Judit
AU - Uhlyarik, Andrea
AU - Lohinszky, Júlia
AU - Stark, Júlia
AU - Huszty, Gergely
AU - Micsik, Tamás
AU - Borka, Katalin
AU - Reismann, Péter
AU - Horányi, János
AU - Igaz, Péter
AU - Tóth, Miklós
TI - Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series
JF - FRONTIERS IN ENDOCRINOLOGY
J2 - FRONT ENDOCRINOL
VL - 13
PY - 2022
PG - 11
SN - 1664-2392
DO - 10.3389/fendo.2022.952418
UR - https://m2.mtmt.hu/api/publication/33153589
ID - 33153589
N1 - Department of Internal Medicine and Oncology, European Reference Network on Rare Endocrine Conditions (ENDO-ERN), Health Care Provider (HCP), Faculty of Medicine, Semmelweis University, Budapest, Hungary
Department of Internal Medicine and Haematology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
Department of Surgery, Transplantation and Gastroenterology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
First Department of Pathology and Experimental Cancer Research, Faculty of Medicine, Semmelweis University, Budapest, Hungary
Department of Pathology, Forensic and Insurance Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary
Department of Endocrinology, European Network for the Study of Adrenal Tumours (ENS@T) Research Center of Excellence, Faculty of Medicine, Semmelweis University, Budapest, Hungary
Magyar Tudományos Akadémia-Semmelweis Egyetem (MTA-SE) Molecular Medicine Research Group, Eötvös Loránd Research Network, Budapest, Hungary
Cited By :1
Export Date: 3 April 2023
Correspondence Address: Tóth, M.; Department of Internal Medicine and Oncology, Hungary; email: toth.miklos@med.semmelweis-univ.hu
AB - ObjectivesThis study aimed to characterise the clinicopathological features and prognostic factors of a large cohort of Hungarian patients with adrenocortical cancer diagnosed between 2000-2021.Patients and methodsThis retrospective study included seventy-four patients (27 men and 47 women) with histologically confirmed adrenocortical cancer in a single tertiary referral endocrine centre. Descriptive statistics were performed, providing summaries of selected clinical and pathological parameters. Clinicopathological factors contributing to overall survival were analysed.ResultsThe median age of patients was 48,5 years (17-84 years) at diagnosis. The majority of cases were diagnosed at ENSAT stage II (39,2%) and stage IV (33,8%). At diagnosis, the median tumour size was 9,0 cm (4,5-20 cm). In 47 patients (71,6%), the tumour was hormonally active. The median overall survival and the 5-year survival rate were 23,5 months (95% CI, 17-30,5 months) and 18,3%, respectively. Primary tumour resection was performed in 68 patients (91,8%); R0 surgical resection was achieved in 30 patients. In univariate Cox regression model, tumours with stages III and IV, high proliferative activity (Ki67-index > 10%), R1-R2 surgical resection state and hormonal activity were associated with poorer survival. Cortisol excess, both isolated and combined with androgen production, was associated with poorer survival. Fifty-five patients were treated with mitotane. The overall survival of patients achieving therapeutic mitotane plasma concentration was significantly better compared to those who never reached it [27.0 (2-175) months vs 18.0 (2-83) months; p<0.05)]. The median age, the distribution of gender, ENSAT stage, resection state and Ki67-index did not differ between these two groups. The time needed to reach the therapeutic range of serum mitotane was 96.5 days (95% CI, 75-133 days).ConclusionOur results confirm previous data that disease stage, mitotic activity, the resection state and the mitotane treatment achieving therapeutic concentration are the most critical parameters influencing the prognosis of adrenocortical cancer. Our data suggest that hormonal activity may be more frequent than described previously, and it is a strong and independent prognostic factor of overall survival. To our knowledge, this is the first single-centre study confirming the prognostic importance of achieving therapeutic mitotane concentration.
LA - English
DB - MTMT
ER -
TY - GEN
AU - Farkas, Katalin
AU - Huszty, Gergely
AU - Varga, Marina
AU - Telkes, Gábor
AU - Cseprekál, Orsolya
AU - Marton, Adrienn
AU - Dinnyés, Izabella
AU - Rem, Lili
AU - Szijártó, Attila
TI - CMV profilaxis alacsony dózisú valganciclovirrel vesetranszplantáció után
PY - 2022
UR - https://m2.mtmt.hu/api/publication/33105564
ID - 33105564
N1 - [előadás]
LA - Hungarian
DB - MTMT
ER -
TY - JOUR
AU - Igaz, Péter
AU - Toth, Geza
AU - Nagy, Péter
AU - Dezső, Katalin
AU - Turai, Péter István
AU - Medvecz, Márta
AU - Wikonkál, Norbert
AU - Huszty, Gergely
AU - Piros, László
AU - Tóth, Erika
AU - Bozsik, Anikó
AU - Likó, István
AU - Patócs, Attila Balázs
AU - Butz, Henriett
TI - Surprising genetic and pathological findings in a patient with giant bilateral periadrenal tumours: PEComas and mutations of PTCH1 in Gorlin-Goltz syndrome
JF - JOURNAL OF MEDICAL GENETICS
J2 - JMG
VL - 59
PY - 2022
IS - 9
SP - 916
EP - 919
PG - 4
SN - 0022-2593
DO - 10.1136/jmedgenet-2021-108082
UR - https://m2.mtmt.hu/api/publication/32545013
ID - 32545013
N1 - Funding Agency and Grant Number: Hungarian National Research, Development and Innovation Office (NKFIH) grantsNational Research, Development & Innovation Office (NRDIO) - Hungary [K134215, K125231]; Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary of the Semmelweis University; Bolyai Research Fellowship of the Hungarian Academy of SciencesHungarian Academy of Sciences; National Laboratories Excellence programme (National Tumorbiology Laboratory project) [NLP-17]
Funding text: Hungarian National Research, Development and Innovation Office (NKFIH) grants K134215 to PI and K125231 to AP. The study was also financed by the Higher Education Institutional Excellence Program-of the Ministry of Human Capacities in Hungary, within the framework of the molecular biology thematic programme of the Semmelweis University. HB is a recipient of Bolyai Research Fellowship of the Hungarian Academy of Sciences. AP and HB acknowledge financial support from the National Laboratories Excellence programme (under the National Tumorbiology Laboratory project (NLP--17)).
LA - English
DB - MTMT
ER -